Elicio Therapeutics reports second quarter 2026 loss of $8.2M as lead candidate misses Phase 2 endpoint

Elicio Therapeutics reported financial results for the second quarter of 2026, marked by a strategic pivot after its lead candidate, ELI-002 7P, failed to meet the primary endpoint in a Phase 2 trial. The company is now focusing on a Phase 1 combination study in metastatic pancreatic cancer and subgroup analysis to refine its adjuvant development strategy.

Key Highlights

• Net loss narrowed to $8.2 million, or $0.43 per share, compared to a $10.6 million loss in the prior-year period, primarily due to lower clinical trial costs.
• Phase 2 AMPLIFY-7P trial for ELI-002 7P did not meet its primary endpoint, though the company noted multiple complete responses in metastatic patients following subsequent checkpoint inhibition.
• Total cash and cash equivalents reached $23.5 million as of June 30, 2026, which, combined with a $15 million July financing, extends the expected operational runway into the first quarter of 2027.